{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:35:56Z","timestamp":1794508556081,"version":"4.9.1"},"reference-count":37,"publisher":"BMJ","issue":"10","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171341"],"award-info":[{"award-number":["82171341"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To identify factors associated with relapse risk and disability in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Between 2016 and 2021, 186 patients with MOGAD were included in the study. Factors associated with a relapsing course, annualised relapse rate (ARR), recurrent relapses under different maintenance treatments and unfavourable disability outcome were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MOGAD affects women (53.8%) slightly more often than men. After a median disease duration of 51.0 months, 60.2% (112\/186) relapsed, with an overall ARR of 0.5. The ARR (0.6 vs 0.4, p=0.049), median Expanded Disability Status Scale (EDSS) score (1 (range 0\u20139.5) vs 1 (range 0\u20133.5), p=0.005) and Visual Functional System Score (VFSS) (0 (range 0\u20136) vs 0 (range 0\u20133), p=0.023) at last visit were higher in adults than in children, and time to first relapse was shorter in adults than in children (4.1 (range 1.0\u2013111.0) vs 12.2 (range 1.3\u2013266.8) months, p=0.001). Myelin oligodendrocyte glycoprotein antibody (MOG-ab) persistence over 1\u2009year was associated with a relapsing course (OR 7.41, 95% CI 2.46 to 22.33, p=0.000), while timely maintenance therapy was associated with a lower ARR (p=0.008). More than four attacks (OR 4.86, 95%\u2009CI 1.65 to 14.28, p=0.004) and poor recovery from the first attack (OR 75.28, 95%\u2009CI 14.45 to 392.05, p=0.000) were associated with an unfavourable outcome (EDSS score \u22652 including VFSS \u22652).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results underscored the importance of timely maintenance treatment to prevent further relapses, especially in adult patients with persistently positive MOG-ab and unsatisfactory recovery from the onset attack.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2022-330901","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T17:20:44Z","timestamp":1686849644000},"page":"825-834","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study"],"prefix":"10.1136","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5308-6325","authenticated-orcid":false,"given":"Jingzi","family":"ZhangBao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-373X","authenticated-orcid":false,"given":"Wenjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-3930","authenticated-orcid":false,"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"2023092610152079000_94.10.825.1","first-page":"443","article-title":"Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin\/oligodendrocyte glycoprotein","volume":"130","author":"Linington","year":"1988","journal-title":"Am J Pathol"},{"key":"2023092610152079000_94.10.825.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1989.tb10930.x"},{"key":"2023092610152079000_94.10.825.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.17.7990"},{"key":"2023092610152079000_94.10.825.4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"2023092610152079000_94.10.825.5","doi-asserted-by":"crossref","unstructured":"in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius S , Ruprecht K , et al . MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13. doi:10.1186\/s12974-016-0718-0","DOI":"10.1186\/s12974-016-0718-0"},{"key":"2023092610152079000_94.10.825.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.01.007"},{"key":"2023092610152079000_94.10.825.7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"2023092610152079000_94.10.825.8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/ene.14654","article-title":"Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients","volume":"28","author":"ZhangBao","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023092610152079000_94.10.825.9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: A single-center cohort study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur J Neurol"},{"key":"2023092610152079000_94.10.825.10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.msard.2017.09.023","article-title":"Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies","volume":"18","author":"Zhou","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"2023092610152079000_94.10.825.11","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005560"},{"key":"2023092610152079000_94.10.825.12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276"},{"key":"2023092610152079000_94.10.825.13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25909"},{"key":"2023092610152079000_94.10.825.14","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: An observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023092610152079000_94.10.825.15","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023092610152079000_94.10.825.16","doi-asserted-by":"crossref","unstructured":"Mariano R , Messina S , Kumar K , et al . Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease. JAMA Netw Open 2019;2:e1912732. doi:10.1001\/jamanetworkopen.2019.12732","DOI":"10.1001\/jamanetworkopen.2019.12732"},{"key":"2023092610152079000_94.10.825.17","doi-asserted-by":"crossref","unstructured":"Satukijchai C , Mariano R , Messina S , et al . Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open 2022;5:e2142780. doi:10.1001\/jamanetworkopen.2021.42780","DOI":"10.1001\/jamanetworkopen.2021.42780"},{"key":"2023092610152079000_94.10.825.18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315603"},{"key":"2023092610152079000_94.10.825.19","doi-asserted-by":"crossref","first-page":"873576","DOI":"10.3389\/fimmu.2022.873576","article-title":"Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: Outcome prediction models","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2023092610152079000_94.10.825.20","doi-asserted-by":"crossref","unstructured":"Kwon YN , Kim B , Kim J-S , et al . Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: Clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflamm 2022;9:e1095. doi:10.1212\/NXI.0000000000001095","DOI":"10.1212\/NXI.0000000000001095"},{"key":"2023092610152079000_94.10.825.21","doi-asserted-by":"crossref","first-page":"752557","DOI":"10.3389\/fimmu.2021.752557","article-title":"Clinical and radiological characteristics of children and adults with first-attack myelin oligodendrocyte glycoprotein antibody disease and analysis of risk factors for predicting the severity at disease onset in central China","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"2023092610152079000_94.10.825.22","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00218-0"},{"key":"2023092610152079000_94.10.825.23","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"key":"2023092610152079000_94.10.825.24","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000000681"},{"key":"2023092610152079000_94.10.825.25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320243"},{"key":"2023092610152079000_94.10.825.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30488-0"},{"key":"2023092610152079000_94.10.825.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0112-x"},{"key":"2023092610152079000_94.10.825.28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023092610152079000_94.10.825.29","doi-asserted-by":"crossref","unstructured":"Cobo-Calvo A , Sep\u00falveda M , d\u2019Indy H , et al . Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. J Neurol 2019;266:806-815. doi:10.1007\/s00415-018-9160-9","DOI":"10.1007\/s00415-018-9160-9"},{"key":"2023092610152079000_94.10.825.30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228c0b1"},{"key":"2023092610152079000_94.10.825.31","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516631038"},{"key":"2023092610152079000_94.10.825.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315998"},{"key":"2023092610152079000_94.10.825.33","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"2023092610152079000_94.10.825.34","doi-asserted-by":"crossref","unstructured":"Huda S , Whittam D , Jackson R , et al . Predictors of relapse in MOG antibody associated disease: A cohort study. BMJ Open 2021;11:e055392. doi:10.1136\/bmjopen-2021-055392","DOI":"10.1136\/bmjopen-2021-055392"},{"key":"2023092610152079000_94.10.825.35","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514555785"},{"key":"2023092610152079000_94.10.825.36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"2023092610152079000_94.10.825.37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0037-1604404","article-title":"MOG spectrum disorders and role of MOG-antibodies in clinical practice","volume":"49","author":"Hennes","year":"2018","journal-title":"Neuropediatrics"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-330901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:17:36Z","timestamp":1695748656000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-330901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/jnnp-2022-330901"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-330901","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}